GLP-1 shortage status

GLP-1 shortage status check: semaglutide, tirzepatide, compounding, and pharmacy access

Patient-safe Peptide12 guide to checking FDA GLP-1 shortage status for semaglutide and tirzepatide, understanding compounding limits, and avoiding unsafe online pharmacy claims.

Educational guideUpdated June 13, 2026

How to verify a GLP-1 access claim

1

Search FDA’s Drug Shortage Database by active ingredient, not only by the brand name: semaglutide injection, tirzepatide injection, liraglutide injection, Wegovy, Ozempic, Zepbound, or Mounjaro.

2

Separate national FDA shortage status from a local pharmacy backorder, insurance prior authorization delay, manufacturer cash-pay supply issue, or telehealth refill queue.

3

Ask the clinician to name the exact product pathway: FDA-approved branded medication, individualized compounded prescription when appropriate and legally available, or no medication.

4

Verify the dispensing pharmacy or manufacturer channel before trusting a checkout page, influencer code, shortage headline, certificate, or vial photo.

5

Reject “generic Ozempic,” “generic Zepbound,” no-prescription GLP-1, research-use vial, salt-form, or guaranteed-availability claims.

6

Use clinician and pharmacy follow-up for missed doses, refills, side effects, label questions, warm shipments, and transitions between branded and compounded pathways.

Direct answer

To check GLP-1 shortage status, use FDA’s Drug Shortage Database and search the active ingredient name, such as semaglutide injection or tirzepatide injection, rather than relying on social media or seller pages. FDA has stated that semaglutide and tirzepatide are not currently on FDA’s drug shortage list and do not appear on the 503B bulks list in its April 1, 2026 GLP-1 compounding policy update. Local pharmacy backorders, insurance delays, cash-pay availability, and online-clinic wait times can still happen, but they are not the same thing as a national FDA shortage or proof that a compounded copy is appropriate or legally available.

Fast answer

A shortage headline is not enough to choose a GLP-1 product

Patients often hear mixed messages about Wegovy, Ozempic, Zepbound, Mounjaro, compounded semaglutide, compounded tirzepatide, cash-pay programs, and local pharmacy supply. The safer first step is to verify whether FDA lists a national shortage, then ask a licensed clinician and the dispensing pharmacy what product is actually available for the individual patient. A temporary backorder at one pharmacy does not automatically make an unapproved or no-prescription GLP-1 safe.

  • FDA’s shortage database is organized around active ingredients and specific drug products, so search both the generic ingredient and the brand when possible.
  • Local supply can vary by dose, pharmacy, payer, manufacturer channel, and timing even when FDA does not list a national shortage.
  • Compounded GLP-1 medications are not FDA-approved finished drug products and should not be marketed as generic branded pens.

FDA compounding context

Shortage status affects some compounding pathways, but it is not the only safety question

FDA’s April 2026 GLP-1 compounding policy update says semaglutide and tirzepatide are not currently on FDA’s drug shortage list and do not appear on the 503B bulks list. FDA also reminds compounders that compounded drugs generally must meet 503A or 503B conditions and that products that are essentially copies of commercially available approved products may not qualify for statutory exemptions unless specific conditions are met. Patients do not need to interpret those rules alone, but they should ask clinics to explain product status without implying FDA approval for a compounded finished medication.

  • A patient-specific compounded prescription is different from a bulk online seller, research-use vial, or “same as brand” checkout offer.
  • A clinic should be able to explain why a compounded option is being discussed, whether it is legally available, and how pharmacy quality is verified.
  • Sellers should not use shortage language, 503B language, or API language to bypass clinician review or hide the dispensing source.

Access planning

Use shortage checks to plan refills, not to improvise doses or sources

If a GLP-1 dose is delayed, the next step is clinician and pharmacy coordination, not self-directed dose stretching, product swapping, or ordering from a no-prescription seller. Patients should ask how to handle missed doses, restarts, dose escalation, nausea or vomiting, diabetes medicines, pregnancy plans, procedures, travel, and side effects before making changes. A responsible access plan also includes total cost, insurance or cash-pay options, refill timing, and what to do if the label or shipment looks wrong.

  • Ask whether another pharmacy, manufacturer channel, dose strength, or clinically appropriate alternative is being considered and who approves the change.
  • Do not use copied dose charts, seller calculators, or social-media titration plans to respond to a delay.
  • Seek urgent care for severe abdominal pain, persistent vomiting, dehydration, fainting, trouble breathing, severe allergic symptoms, or chest pain.

Seller red flags

Unsafe GLP-1 sellers often turn supply anxiety into urgency pressure

FDA warns that unapproved GLP-1 products do not undergo FDA review for safety, effectiveness, or quality before marketing. Patients should be cautious when a website treats shortage news as a reason to skip prescriptions, hide the pharmacy, sell research-use products for human treatment, claim “FDA-approved compounded” status, or promise a specific outcome. Verification should happen before payment whenever possible, and suspicious labels or warm shipments should be paused and reviewed with the clinic or pharmacy before use.

  • Red flags include no prescription, no named licensed pharmacy, suspiciously low price, “generic Ozempic,” “generic Zepbound,” salt-form claims, and research-use labels.
  • A GLP-1 package that arrives warm, leaking, damaged, expired, misspelled, unlabeled, or different than expected should be reviewed before use.
  • Document package photos, label information, lot or batch numbers, tracking details, storage concerns, and symptoms when escalating a quality issue.

Patient safety checklist

Questions to ask before relying on a GLP-1 shortage or access claim

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

What does FDA’s Drug Shortage Database show today for the active ingredient and product I am considering?

✓

Is this a national FDA-listed shortage, a local pharmacy backorder, an insurance delay, a dose-strength issue, or a clinic workflow delay?

✓

Is the proposed product Wegovy, Ozempic, Zepbound, Mounjaro, another FDA-approved medication, an individualized compounded prescription, or not appropriate for me?

✓

Who is the licensed clinician responsible for the prescription decision, dose changes, contraindication review, side-effect plan, and follow-up?

✓

Which pharmacy or manufacturer channel will dispense the medication, and can I verify its name, address, license, and contact path?

✓

If compounding is discussed, how does the clinic explain legal availability, product status, patient-specific need, pharmacy quality, and the fact that compounded finished drugs are not FDA-approved?

✓

What should I do if my medication is delayed, unavailable, warm, damaged, mislabeled, expired, missing supplies, or different from the prescription?

✓

What red flags would make this seller unsafe, such as no prescription, research-use language, salt forms, guaranteed outcomes, bulk vials, hidden sourcing, or copied dose charts?

FAQs

Short answers for patients

How do I check if semaglutide or tirzepatide is in shortage?

Use FDA’s Drug Shortage Database and search by active ingredient, such as semaglutide injection or tirzepatide injection. Confirm the date and product details, then ask your clinician or pharmacist how that status applies to your prescription, dose, insurance, and local pharmacy availability.

Does a local pharmacy backorder mean there is an FDA shortage?

No. A local backorder can happen because of dose-strength supply, wholesaler timing, insurance processing, pharmacy inventory, or manufacturer channel issues. FDA shortage status is a national regulatory database signal, not a guarantee that every local pharmacy has every dose available.

Can compounded semaglutide or tirzepatide be called FDA-approved?

No. FDA-approved branded drugs and individualized compounded prescriptions are different pathways. FDA says compounded drugs are not FDA-approved, which means FDA does not review the finished compounded drug for safety, effectiveness, or quality before marketing.

Does shortage status automatically make compounded GLP-1 medication appropriate?

No. Shortage status can affect certain compounding rules, but the patient still needs clinician review, pharmacy-quality verification, a clear prescription, legal availability, product-status transparency, side-effect planning, and follow-up.

What should I do if my GLP-1 refill is delayed?

Contact the prescribing clinic and dispensing pharmacy before changing doses or sourcing a replacement. Ask about missed-dose instructions, clinically appropriate alternatives, timing, side effects, insurance or cash-pay options, and when urgent care is needed.

Why does Peptide12 separate branded, compounded, and no-prescription GLP-1 claims?

The safety and regulatory questions are different. Peptide12 frames GLP-1 access around licensed clinician review, legitimate pharmacy or manufacturer channels, transparent product status, label and storage checks, follow-up, and avoidance of no-prescription or research-use sellers.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilizeFDA: Drug shortagesFDA: FDA's concerns with unapproved GLP-1 drugs used for weight lossFDA: BeSafeRx — your source for online pharmacy informationDailyMed: Wegovy prescribing informationDailyMed: Zepbound prescribing informationPeptide12: FDA 503B GLP-1 bulks list proposalPeptide12: Fake GLP-1 online pharmacy checklistPeptide12: Peptide pharmacy quality checklistPeptide12: 503A vs 503B compounding pharmacyPeptide12: Compounded vs branded peptide medicationsPeptide12: Wegovy vs compounded semaglutidePeptide12: Zepbound vs compounded tirzepatidePeptide12: Semaglutide salt-form safetyPeptide12: GLP-1 refill and follow-up questionsPeptide12: Online peptide medication recalls and lot numbersPeptide12: How online peptide therapy works